Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.
GKOS - Glaukos Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$192.90
DETAILS
HIGH:
$215.00
LOW:
$150.00
MEDIAN:
$195.00
CONSENSUS:
$192.90
UPSIDE:
17.02%
Stock News
Glaukos: The Second J-Code Rewrites The Risk Math
Glaukos is transitioning from a single-product reimbursement story to a diversified ophthalmic pharmaceutical platform with two J-coded drugs and strong operating leverage. Q2 net sales grew 50% YoY to $185.6M, driven by iDose TR and the Epioxa launch, with non-GAAP gross margin reaching 85% and breakeven P&L. Management raised 2026 net sales guidance to $680–700M, with iDose TR sales expected at $275–280M and corneal health growth of 20%+.
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Ophthalmic pharmaceutical and medical technology firm Glaukos Corporation (NYSE:GKOS) reported successful topline outcomes from its latest Phase 4 clinical study.
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced positive topline results from the Phase 4 prospective, randomized, controlled clinical trial (GLK-101-04) evaluating iDose® TR administered in conjunction with cataract surgery compared to cataract surgery alone in patients with open-angle glaucoma (OA.
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
Glaukos Corporation (NYSE:GKOS) reported three-year trial results for its non-invasive keratoconus treatment while simultaneously securing an exclusive licensing deal to broaden its pipeline of retinal disease therapies.
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced an exclusive license agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, a novel tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macula edema (DME), diabetic retinopat.
Glaukos says late-stage eye disease treatment shows lasting benefits after single dose
Glaukos said on Wednesday patients treated with its late-stage eye disease therapy maintained improvements in vision and corneal shape three years after a single treatment for keratoconus, a disease that can progressively distort vision.
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the company's groundbreaking epi-on corneal cross-linking therapy for the treatment of keratoconus, a sigh.
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release third quarter 2026 financial results after the market close on Wednesday, October 28, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on October 28, 2026. A link.
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.
Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the launch of Could it be KC?, a new disease awareness and educational campaign launching today with expanding activities planned in 2027 aimed at improving recognition and earlier detection of keratoconus (KC), a rare, progressive, sight-threatening c.
Glaukos Corporation $GKOS Shares Sold by Squarepoint Ops LLC
Squarepoint Ops LLC reduced its holdings in shares of Glaukos Corporation (NYSE: GKOS) by 86.9% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,167 shares of the medical instruments supplier's stock after selling 93,882 shares during the period.
Corient Private Wealth LP Takes Position in Glaukos Corporation $GKOS
Corient Private Wealth LP acquired a new stake in Glaukos Corporation (NYSE: GKOS) during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 57,048 shares of the medical instruments supplier's stock, valued at approximately $7,973,000. Corient Private Wealth LP owned approximately 0.10% of Glaukos at the
Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?
Glaukos Corporation $GKOS Stock Holdings Trimmed by Algert Global LLC
Algert Global LLC lessened its holdings in shares of Glaukos Corporation (NYSE: GKOS) by 43.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 30,871 shares of the medical instruments supplier's stock after selling 23,330 shares during the quarter. Algert Global LLC owned about 0.05% of
61,957 Shares in Glaukos Corporation $GKOS Purchased by Deutsche Bank AG
Deutsche Bank AG acquired a new stake in Glaukos Corporation (NYSE: GKOS) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 61,957 shares of the medical instruments supplier's stock, valued at approximately $8,659,000. Deutsche Bank AG owned about 0.11% of Glaukos at the
GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.
Glaukos Announces Participation in Wells Fargo Healthcare Conference
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 3:00 p.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors.
Price Targets
Glaukos price target raised to $190 from $185 at Mizuho
$190.00
(was $168.02)
Mizuho Securities
Glaukos price target raised to $205 from $202 at BTIG
$205.00
(was $166.06)
Ryan Zimmerman
·
BTIG
Glaukos price target raised to $210 from $190 at Jefferies
$210.00
(was $162.24)
Jefferies
Glaukos price target raised to $202 from $193 at BTIG
$202.00
(was $189.55)
BTIG
Glaukos price target raised to $195 from $168 at H.C. Wainwright
$195.00
(was $170.67)
H.C. Wainwright
Glaukos price target raised to $190 from $175 at Stifel
$190.00
(was $161.66)
Stifel Nicolaus
Glaukos price target raised to $195 from $165 at Piper Sandler
$195.00
(was $161.66)
Matt O'Brien
·
Piper Sandler
Glaukos price target raised to $178 from $138 at Wells Fargo
$178.00
(was $161.66)
Larry Biegelsen
·
Wells Fargo
Glaukos Corporation (GKOS) PT Raised to $201 at Needham
$201.00
(was $161.66)
David Saxon
·
Needham
Glaukos Corporation (GKOS) PT Raised to $215 at Truist Securities
$215.00
(was $161.66)
Richard Newitter
·
Truist Financial
Glaukos assumed with Neutral from Buy at UBS
$150.00
(was $151.91)
UBS
Glaukos price target raised to $180 from $160 at Truist
$180.00
(was $159.17)
Truist Financial
Glaukos price target raised to $164 from $162 at BTIG
$164.00
(was $152.72)
BTIG
Glaukos initiated with a Buy at H.C. Wainwright
$168.00
(was $148.34)
H.C. Wainwright
Glaukos Corporation (GKOS) PT Raised to $150 at Needham
$150.00
(was $127.53)
David Saxon
·
Needham
Glaukos Corporation (GKOS) PT Raised to $162 at BTIG
$162.00
(was $143.82)
Ryan Zimmerman
·
BTIG
Glaukos price target raised to $170 from $160 at Stifel
$170.00
(was $135.57)
Thomas Stephan
·
Stifel Nicolaus
Glaukos price target raised to $141 from $131 at BTIG
$141.00
(was $116.96)
BTIG
Glaukos price target raised to $136 from $127 at Needham
$136.00
(was $116.96)
Needham
Glaukos price target raised to $127 from $125 at Needham
$127.00
(was $106.64)
David Saxon
·
Needham